1. Home
  2. ARCT vs DGICB Comparison

ARCT vs DGICB Comparison

Compare ARCT & DGICB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARCT
  • DGICB
  • Stock Information
  • Founded
  • ARCT 2013
  • DGICB 1986
  • Country
  • ARCT United States
  • DGICB United States
  • Employees
  • ARCT N/A
  • DGICB N/A
  • Industry
  • ARCT Biotechnology: Pharmaceutical Preparations
  • DGICB Property-Casualty Insurers
  • Sector
  • ARCT Health Care
  • DGICB Finance
  • Exchange
  • ARCT Nasdaq
  • DGICB Nasdaq
  • Market Cap
  • ARCT 526.5M
  • DGICB 562.0M
  • IPO Year
  • ARCT N/A
  • DGICB N/A
  • Fundamental
  • Price
  • ARCT $10.59
  • DGICB $15.33
  • Analyst Decision
  • ARCT Buy
  • DGICB
  • Analyst Count
  • ARCT 10
  • DGICB 0
  • Target Price
  • ARCT $35.25
  • DGICB N/A
  • AVG Volume (30 Days)
  • ARCT 2.1M
  • DGICB 1.2K
  • Earning Date
  • ARCT 11-07-2025
  • DGICB 10-30-2025
  • Dividend Yield
  • ARCT N/A
  • DGICB 4.14%
  • EPS Growth
  • ARCT N/A
  • DGICB 965.80
  • EPS
  • ARCT N/A
  • DGICB 2.34
  • Revenue
  • ARCT $122,122,000.00
  • DGICB $993,644,532.00
  • Revenue This Year
  • ARCT N/A
  • DGICB $2.26
  • Revenue Next Year
  • ARCT $34.32
  • DGICB $3.46
  • P/E Ratio
  • ARCT N/A
  • DGICB $8.23
  • Revenue Growth
  • ARCT N/A
  • DGICB 3.36
  • 52 Week Low
  • ARCT $8.04
  • DGICB $13.19
  • 52 Week High
  • ARCT $24.17
  • DGICB $20.46
  • Technical
  • Relative Strength Index (RSI)
  • ARCT 31.16
  • DGICB 49.50
  • Support Level
  • ARCT $9.19
  • DGICB $14.87
  • Resistance Level
  • ARCT $12.10
  • DGICB $15.87
  • Average True Range (ATR)
  • ARCT 1.78
  • DGICB 0.27
  • MACD
  • ARCT -1.35
  • DGICB 0.11
  • Stochastic Oscillator
  • ARCT 9.36
  • DGICB 33.76

About ARCT Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.

About DGICB Donegal Group Inc. Class B

Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.

Share on Social Networks: